Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)

ConclusionIn summary, these data suggest a promising potential of domatinostat in combination with immunotherapy to improve the outcome of refractory cancer patients.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research